09.2024

Orbit Genomics was awarded a $2 million Direct to Phase II SBIR Grant from NIH/NCI to develop a subtyping lung cancer test. This test will be the second generation of OrbiSeq-L, a simple blood test that diagnoses lung cancer in patients that have indeterminate pulmonary nodules. The added subtyping capability will substantially expand the use of our test while improving patient outcomes, further reducing the need for biopsies, and significantly reducing costs.

Direct to Phase II (D2P2) is a Small Business Innovation Research (SBIR) award that allows small businesses to move directly into Phase II of research and development without receiving a Phase I award. This is possible if the business has already completed Phase I-like feasibility studies using other funding sources.

Dede Willis, CEO, says: “the grant review process featured an exceptionally rigorous peer reviewed evaluation of our technology platform by experts internal and external to NIH/NCI, providing robust validation of our scientific and business approach and its potential to drive innovation in the field.”